Wednesday, December 07, 2011

Clinical Trials: Solanezumab in Alzheimer's Disease

From Bloomberg:

Eli Lilly Shares Rise on Alzheimer’s Drug Hopes
By Drew Armstrong and Robert Langreth
Dec 6, 2011


"Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s disease. Pfizer Inc. (PFE), Johnson & Johnson and Elan are testing bapineuzumab, a similar drug."


Read the article

Labels: , , , , , ,


Post a Comment

<< Home